Top

European Journal of Nutrition

Published in:

Open Access 01-08-2021 | Probiotics | Review

Diet supporting therapy for inflammatory bowel diseases

Authors: Justyna Kikut, Nina Konecka, Maciej Ziętek, Danuta Kulpa, Małgorzata Szczuko

Published in: European Journal of Nutrition | Issue 5/2021

Abstract

Purpose

Non-specific inflammatory bowel diseases (IBD) include Crohn's disease and ulcerative colitis. More and more often attention is paid to the possibility of dietary support for inflammatory bowel diseases.

Methods

The following review article considers the role of dietary components in the treatment of IBD as: pteridines, probiotics, bovine immunoglobulin, vitamin D, omega-3, flavonoids, polyphenols, curcumin and phosphatidylcholine. The article also discusses plant raw materials of arjuna, soy protein and nettles, trying to summarize their effect on quenching the inflammatory process within the intestines. This review focuses on the possibilities of dietary components and supplementation use to improve the pharmacotherapy response as well as the general clinical patients’ condition.

Results

The mechanism of action of supportive therapy is based on reduction in oxidative stress, maintaining the adequate balance between Th1 and Th2 lymphocytes by affecting cytokines, increasing riboflavin supply for macrophages, increasing expression of vitamin D receptor, regulation by decreasing the expression of NF-κB in liver cells and ability to inhibit the COX2 entrance and inactivate prostaglandins that are involved in the inflammatory process and 12-lipoxygenase pathway inhibition.

Conclusion

Considering clinical researches, it seems that the use of the above-mentioned ingredients in the diet of patients suffering IBD may positively influence the treatment process and maintenance of remission.

Kordjazy N, Haj-Mirzaian A, Haj-Mirzaian A et al (2018) Role of toll-like receptors in inflammatory bowel disease. Pharmacol Res 129:204–215. https://doi.org/10.1016/j.phrs.2017.11.017CrossRefPubMed

Ashton JJ, Ennis S, Beattie RM (2017) Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health 1:147–158. https://doi.org/10.1016/S2352-4642(17)30017-2CrossRefPubMed

Ramos GP, Papadakis KA (2019) Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc 94:155–165. https://doi.org/10.1016/j.mayocp.2018.09.013CrossRefPubMed

Zhang Y-Z, Li Y-Y (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20:91–99. https://doi.org/10.3748/wjg.v20.i1.91CrossRefPubMedPubMedCentral

Lewis JD, Abreu MT (2017) Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology 152:398-414.e6. https://doi.org/10.1053/j.gastro.2016.10.019CrossRefPubMed

Hooper KM, Barlow PG, Stevens C, Henderson P (2017) Inflammatory bowel disease drugs: a focus on autophagy. J Crohns Colitis 11:118–127. https://doi.org/10.1093/ecco-jcc/jjw127CrossRefPubMed

Radwan P (2008) Leczenie Farmakologiczne choroby Leśniowskiego-Crohna. Choroba Leśniowskiego-Crohna-100 lat diagnostyki i terapii, 1st edn. Termedia Poznań, Poznań, pp 113–130

Larussa T, Imeneo M, Luzza F (2017) Potential role of nutraceutical compounds in inflammatory bowel disease. World J Gastroenterol 23:2483–2492. https://doi.org/10.3748/wjg.v23.i14.2483CrossRefPubMedPubMedCentral

Julia C, Meunier N, Touvier M et al (2013) Dietary patterns and risk of elevated C-reactive protein concentrations 12 years later. Br J Nutr 110:747–754. https://doi.org/10.1017/S0007114512005636CrossRefPubMed

10.

Sobiś J, Kunert Ł, Sołtysik M et al (2015) Omega-3 polyunsaturated fatty acids in the prevention of affective disorders. Selected epidemiological data concering the use of omega-3 in the prevention of affective disorders. Psychiatria 12:147–152

11.

Akbaraly TN, Shipley MJ, Ferrie JE et al (2015) Long-term adherence to healthy dietary guidelines and chronic inflammation in the prospective Whitehall II study. Am J Med 128:152-160.e4. https://doi.org/10.1016/j.amjmed.2014.10.002CrossRefPubMedPubMedCentral

12.

Lordan R, Tsoupras A, Zabetakis I (2017) Phospholipids of animal and marine origin: structure, function, and anti-inflammatory properties. Molecules. https://doi.org/10.3390/molecules22111964CrossRefPubMedPubMedCentral

13.

Shen C, Dillissen E, Kasran A et al (2006) Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice. J Interferon Cytokine Res 26:575–582. https://doi.org/10.1089/jir.2006.26.575CrossRefPubMed

14.

Piotrowska A, Iżykowska I, Podhorska-Okołów M et al (2008) The structure of NF-kB family proteins and their role in apoptosis. Postępy Higieny i Medycyny Doświadczalnej 62:64–74PubMed

15.

Ahmed S, Dewan MZ, Xu R (2014) Nuclear factor-kappaB in inflammatory bowel disease and colorectal cancer. Am J Dig Dis 1:84–96

16.

Mazur-Bialy AI, Buchala B, Plytycz B (2013) Riboflavin deprivation inhibits macrophage viability and activity—a study on the RAW 264.7 cell line. Br J Nutr 110:509–514. https://doi.org/10.1017/S0007114512005351CrossRefPubMed

17.

Szeliga J, Sóndka Z, Jackowski M et al (2007) The outline of immunopathogenesis of Crohn’s disease with special consideration of NOD2/CARD15 gene polymorphism. Gastroenteroloia Polska 14:129–133

18.

Head K, Jurenka JS (2004) Inflammatory bowel disease. Part II: Crohn’s disease—pathophysiology and conventional and alternative treatment options. Altern Med Rev 9:360–401PubMed

19.

Guirado A, López Sánchez JI, Ruiz-Alcaraz AJ et al (2013) First synthesis and biological evaluation of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines as inhibitors of TNF-α and IL-6. Eur J Med Chem 66:269–275. https://doi.org/10.1016/j.ejmech.2013.05.020CrossRefPubMed

20.

Jenny M, Klieber M, Zaknun D et al (2011) In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors. Inflamm Res 60:127–135. https://doi.org/10.1007/s00011-010-0244-yCrossRefPubMed

21.

Husain N, Tokoro K, Popov JM et al (2013) Neopterin concentration as an index of disease activity in Crohn’s disease and ulcerative colitis. J Clin Gastroenterol 47:246–251. https://doi.org/10.1097/MCG.0b013e3182582cdbCrossRefPubMed

22.

Maier E, Kurz K, Jenny M et al (2010) Food preservatives sodium benzoate and propionic acid and colorant curcumin suppress Th1-type immune response in vitro. Food Chem Toxicol 48:1950–1956. https://doi.org/10.1016/j.fct.2010.04.042CrossRefPubMed

23.

Cıralı C, Ulusoy E, Kume T, Arslan N (2018) Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines. World J Pediatr 14:448–453. https://doi.org/10.1007/s12519-018-0144-8CrossRefPubMed

24.

Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45:1462–1464. https://doi.org/10.1023/a:1005588911207CrossRefPubMed

25.

Bourreille A, Cadiot G, Le Dreau G et al (2013) Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol 11:982–987. https://doi.org/10.1016/j.cgh.2013.02.021CrossRefPubMed

26.

Sichetti M, De Marco S, Pagiotti R et al (2018) Anti-inflammatory effect of multistrain probiotic formulation (L. rhamnosus, B. lactis, and B. longum). Nutrition 53:95–102. https://doi.org/10.1016/j.nut.2018.02.005CrossRefPubMed

27.

Fedorak RN, Feagan BG, Hotte N et al (2015) The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol 13:928-935.e2. https://doi.org/10.1016/j.cgh.2014.10.031CrossRefPubMed

28.

Le B, Yang SH (2018) Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease. Toxicol Rep 5:314–317. https://doi.org/10.1016/j.toxrep.2018.02.007CrossRefPubMedPubMedCentral

29.

Pathmakanthan S, Li CKF, Cowie J, Hawkey CJ (2004) Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 19:166–173. https://doi.org/10.1111/j.1440-1746.2004.03181.xCrossRefPubMed

30.

Wu S, Yoon S, Zhang Y-G et al (2015) Vitamin D receptor pathway is required for probiotic protection in colitis. Am J Physiol Gastrointest Liver Physiol 309:G341-349. https://doi.org/10.1152/ajpgi.00105.2015CrossRefPubMedPubMedCentral

31.

Ahn Y-S, Park MY, Shin J-H et al (2014) Lysate of probiotic Lactobacillus plantarum K8 modulate the mucosal inflammatory system in dextran sulfate sodium-induced colitic rats. Korean J Food Sci Anim Resour 34:829–835. https://doi.org/10.5851/kosfa.2014.34.6.829CrossRefPubMedPubMedCentral

32.

Yin M, Yan X, Weng W et al (2018) Micro integral membrane protein (MIMP), a Newly discovered anti-inflammatory protein of Lactobacillus plantarum, enhances the gut barrier and modulates microbiota and inflammatory cytokines. Cell Physiol Biochem 45:474–490. https://doi.org/10.1159/000487027CrossRefPubMed

33.

Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG, (2018) Protective effect of the riboflavin-overproducing strain Lactobacillus plantarum CRL2130 on intestinal mucositis in mice. Nutrition 54:165–172. https://doi.org/10.1016/j.nut.2018.03.056CrossRefPubMed

34.

Derwa Y, Gracie DJ, Hamlin PJ, Ford AC (2017) Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 46:389–400. https://doi.org/10.1111/apt.14203CrossRefPubMed

35.

Kruis W, Frič P, Pokrotnieks J et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623. https://doi.org/10.1136/gut.2003.037747CrossRefPubMedPubMedCentral

36.

Probiotics and Prebiotics|World Gastroenterology Organisation. https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. Accessed 9 Dec 2019

37.

Shafran I, Burgunder P, Wei D et al (2015) Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin. Therap Adv Gastroenterol 8:331–339. https://doi.org/10.1177/1756283X15593693CrossRefPubMedPubMedCentral

38.

Beauerle BD, Burnett BP, Dryden GW (2015) Successful management of refractory ulcerative colitis with orally administered serum-derived bovine immunoglobulin therapy. Clin Case Rep Rev 1:90–92. https://doi.org/10.15761/ccrr.1000130CrossRef

39.

Shaw AL, Tomanelli A, Bradshaw TP et al (2017) Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective. Patient Prefer Adher 11:1001–1007. https://doi.org/10.2147/PPA.S134792CrossRef

40.

Liaquat H, Ashat M, Stocker A et al (2018) Clinical efficacy of serum-derived bovine immunoglobulin in patients with refractory inflammatory bowel disease. Am J Med Sci 356:531–536. https://doi.org/10.1016/j.amjms.2018.08.019CrossRefPubMed

41.

Soriano RA, Ramos-Soriano AG (2017) Clinical and pathologic remission of pediatric ulcerative colitis with serum-derived bovine immunoglobulin added to the standard treatment regimen. CRG 11:335–343. https://doi.org/10.1159/000475923CrossRefPubMedPubMedCentral

42.

Shafran I, Young HE, Wei D et al (2016) Pilot pharmacoeconomic analysis of serum-derived bovine immunoglobulin use in IBD. Am J Pharm Benefits 8:34–41

43.

Alhassan Mohammed H, Mirshafiey A, Vahedi H et al (2017) Immunoregulation of inflammatory and inhibitory cytokines by vitamin D3 in patients with inflammatory bowel diseases. Scand J Immunol 85:386–394. https://doi.org/10.1111/sji.12547CrossRefPubMed

44.

Del Pinto R, Ferri C, Cominelli F (2017) Vitamin D axis in inflammatory bowel diseases: role, current uses and future perspectives. Int J Mol Sci. https://doi.org/10.3390/ijms18112360CrossRefPubMedPubMedCentral

45.

Lin Z, Li W (2016) The roles of vitamin D and its analogs in inflammatory diseases. Curr Top Med Chem 16:1242–1261. https://doi.org/10.2174/1568026615666150915111557CrossRefPubMed

46.

Blanck S, Aberra F (2013) Vitamin D deficiency is associated with ulcerative colitis disease activity. Dig Dis Sci 58:1698–1702. https://doi.org/10.1007/s10620-012-2531-7CrossRefPubMed

47.

Laird E, McNulty H, Ward M et al (2014) Vitamin D deficiency is associated with inflammation in older Irish adults. J Clin Endocrinol Metab 99:1807–1815. https://doi.org/10.1210/jc.2013-3507CrossRefPubMed

48.

Jørgensen SP, Agnholt J, Glerup H et al (2010) Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 32:377–383. https://doi.org/10.1111/j.1365-2036.2010.04355.xCrossRefPubMed

49.

Del Pinto R, Pietropaoli D, Chandar AK et al (2015) Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis 21:2708–2717. https://doi.org/10.1097/MIB.0000000000000546CrossRefPubMed

50.

Forbes A, Escher J, Hébuterne X et al (2017) ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr 36:321–347. https://doi.org/10.1016/j.clnu.2016.12.027CrossRefPubMed

51.

He K, Liu K, Daviglus ML et al (2009) Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 103:1238–1243. https://doi.org/10.1016/j.amjcard.2009.01.016CrossRefPubMedPubMedCentral

52.

Charpentier C, Chan R, Salameh E et al (2018) Dietary n-3 PUFA may attenuate experimental colitis. Mediators Inflamm 2018:8430614. https://doi.org/10.1155/2018/8430614CrossRefPubMedPubMedCentral

53.

Mbodji K, Charpentier C, Guérin C et al (2013) Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis. J Nutr Biochem 24:700–705. https://doi.org/10.1016/j.jnutbio.2012.03.022CrossRefPubMed

54.

Turner D, Shah PS, Steinhart AH et al (2011) Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 17:336–345. https://doi.org/10.1002/ibd.21374CrossRefPubMed

55.

Oledzka R (2007) Nutraceutyki, zywnosc funkcjonalna—rola i bezpieczenstwo stosowania. Bromatologia i Chemia Toksykologiczna 40:1–8

56.

Joo M, Kim HS, Kwon TH et al (2015) Anti-inflammatory effects of flavonoids on TNBS-induced colitis of rats. Korean J Physiol Pharmacol 19:43–50. https://doi.org/10.4196/kjpp.2015.19.1.43CrossRefPubMed

57.

Zhou K, Cheng R, Liu B et al (2018) Eupatilin ameliorates dextran sulphate sodium-induced colitis in mice partly through promoting AMPK activation. Phytomedicine 46:46–56. https://doi.org/10.1016/j.phymed.2018.04.033CrossRefPubMed

58.

Włochal M, Grzymisławski M (2016) New trends in the dietary treatment of inflammatory bowel diseases. Pielęgniarstwo i Zdrowie Publiczne Nurs Public Health 6:149–158. https://doi.org/10.17219/pzp/61571CrossRef

59.

Mascaraque C, González R, Suárez MD et al (2015) Intestinal anti-inflammatory activity of apigenin K in two rat colitis models induced by trinitrobenzenesulfonic acid and dextran sulphate sodium. Br J Nutr 113:618–626. https://doi.org/10.1017/S0007114514004292CrossRefPubMed

60.

Sadraei H, Asghari G, Khanabadi M, Minaiyan M (2017) Anti-inflammatory effect of apigenin and hydroalcoholic extract of Dracocephalum kotschyi on acetic acid-induced colitis in rats. Res Pharm Sci 12:322–329. https://doi.org/10.4103/1735-5362.212050CrossRefPubMedPubMedCentral

61.

Ben-Arye E, Goldin E, Wengrower D et al (2002) Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37:444–449. https://doi.org/10.1080/003655202317316088CrossRefPubMed

62.

Boussenna A, Cholet J, Goncalves-Mendes N et al (2016) Polyphenol-rich grape pomace extracts protect against dextran sulfate sodium-induced colitis in rats. J Sci Food Agric 96:1260–1268. https://doi.org/10.1002/jsfa.7214CrossRefPubMed

63.

D’Argenio G, Mazzone G, Tuccillo C et al (2012) Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. Dig Liver Dis 44:555–562. https://doi.org/10.1016/j.dld.2012.01.009CrossRefPubMed

64.

Parkar SG, Stevenson DE, Skinner MA (2008) The potential influence of fruit polyphenols on colonic microflora and human gut health. Int J Food Microbiol 124:295–298. https://doi.org/10.1016/j.ijfoodmicro.2008.03.017CrossRefPubMed

65.

Sun X, Du M, Navarre DA, Zhu M-J (2018) Purple potato extract promotes intestinal epithelial differentiation and barrier function by activating AMP-activated protein kinase. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201700536CrossRefPubMedPubMedCentral

66.

Muanprasat C, Sirianant L, Sawasvirojwong S et al (2013) Activation of AMP-activated protein kinase by a plant-derived dihydroisosteviol in human intestinal epithelial cell. Biol Pharm Bull 36:522–528. https://doi.org/10.1248/bpb.b12-00711CrossRefPubMed

67.

Sun X, Yang Q, Rogers CJ et al (2017) AMPK improves gut epithelial differentiation and barrier function via regulating Cdx2 expression. Cell Death Differ 24:819–831. https://doi.org/10.1038/cdd.2017.14CrossRefPubMedPubMedCentral

68.

Suskind DL, Wahbeh G, Burpee T et al (2013) Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr 56:277–279. https://doi.org/10.1097/MPG.0b013e318276977dCrossRefPubMedPubMedCentral

69.

Garg SK, Ahuja V, Sankar MJ et al (2012) Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 10:CD008424. https://doi.org/10.1002/14651858.CD008424.pub2CrossRef

70.

Iqbal U, Anwar H, Quadri AA (2018) Use of curcumin in achieving clinical and endoscopic remission in ulcerative colitis: a systematic review and meta-analysis. Am J Med Sci 356:350–356. https://doi.org/10.1016/j.amjms.2018.06.023CrossRefPubMed

71.

Hanai H, Iida T, Takeuchi K et al (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4:1502–1506. https://doi.org/10.1016/j.cgh.2006.08.008CrossRefPubMed

72.

Jiménez-Flores LM, López-Briones S, Macías-Cervantes MH et al (2014) A PPARγ, NF-κB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver. Molecules 19:8289–8302. https://doi.org/10.3390/molecules19068289CrossRefPubMedPubMedCentral

73.

Ehehalt R, Wagenblast J, Erben G et al (2004) Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 39:737–742. https://doi.org/10.1080/00365520410006233CrossRefPubMed

74.

Vetter M, Neurath MF (2017) Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 10:773–790. https://doi.org/10.1177/1756283X17727388CrossRefPubMedPubMedCentral

75.

Treede I, Braun A, Jeliaskova P et al (2009) TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol 9:53. https://doi.org/10.1186/1471-230X-9-53CrossRefPubMedPubMedCentral

76.

Amadei F, Fröhlich B, Stremmel W, Tanaka M (2018) Nonclassical interactions of phosphatidylcholine with mucin protect intestinal surfaces: a microinterferometry study. Langmuir 34:14046–14057. https://doi.org/10.1021/acs.langmuir.8b03035CrossRefPubMed

77.

Stremmel W, Merle U, Zahn A et al (2005) Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54:966–971. https://doi.org/10.1136/gut.2004.052316CrossRefPubMedPubMedCentral

78.

Amalraj A, Gopi S (2017) Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review. J Tradit Complement Med 7:65–78. https://doi.org/10.1016/j.jtcme.2016.02.003CrossRefPubMed

79.

Cota D, Mishra S, Shengule S (2019) Beneficial role of Terminalia arjuna hydro-alcoholic extract in colitis and its possible mechanism. J Ethnopharmacol 230:117–125. https://doi.org/10.1016/j.jep.2018.10.020CrossRefPubMed

80.

Ahmad MS, Ahmad S, Gautam B et al (2014) Terminalia arjuna, a herbal remedy against environmental carcinogenicity: an in vitro and in vivo study. Egypt J Med Hum Genet 15:61–67. https://doi.org/10.1016/j.ejmhg.2013.10.004CrossRef

81.

Metzger CE, Narayanan SA, Zawieja DC, Bloomfield SA (2019) A moderately elevated soy protein diet mitigates inflammatory changes in gut and in bone turnover during chronic TNBS-induced inflammatory bowel disease. Appl Physiol Nutr Metab 44:595–605. https://doi.org/10.1139/apnm-2018-0514CrossRefPubMed

82.

Francišković M, Gonzalez-Pérez R, Orčić D et al (2017) Chemical composition and immuno-modulatory effects of Urtica dioica L. (Stinging Nettle) extracts. Phytother Res 31:1183–1191. https://doi.org/10.1002/ptr.5836CrossRefPubMed

83.

Emsley J (2011) Nature’s building blocks: an A–Z guide to the elements. OUP, Oxford

84.

Nematgorgani S, Agah S, Shidfar F et al (2017) Effects of Urtica dioica leaf extract on inflammation, oxidative stress, ESR, blood cell count and quality of life in patients with inflammatory bowel disease. J Herb Med 9:32–41. https://doi.org/10.1016/j.hermed.2017.05.002CrossRef

Title: Diet supporting therapy for inflammatory bowel diseases
Authors: Justyna Kikut
Nina Konecka
Maciej Ziętek
Danuta Kulpa
Małgorzata Szczuko
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Probiotics
Chronic Inflammatory Bowel Disease
Published in: European Journal of Nutrition / Issue 5/2021
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-021-02489-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2021

Can the supplementary consumption of baobab (Adansonia digitata L.) fruit pulp improve the hemoglobin levels and iron status of schoolchildren in Kenya? Findings of a randomized controlled intervention trial

100% Fruit juice intake and cardiovascular risk: a systematic review and meta-analysis of prospective and randomised controlled studies

The overall diet quality in childhood is prospectively associated with the timing of puberty

Describing a new food group classification system for UK biobank: analysis of food groups and sources of macro- and micronutrients in 208,200 participants

Dietary intakes, sources, and determinants of free sugars amongst Lebanese children and adolescents: findings from two national surveys

Altered nutrition behavior during COVID-19 pandemic lockdown in young adults

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage